Insider · CIK 0001437435

Tessier-Lavigne Marc

Reports to the SEC for 6 companies · SO SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001437435

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-06-03	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+6,037 sh	—	—	1,886,576
2025-06-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+18.1K sh	—	—	18,111
2024-05-31	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+5,967 sh	—	—	1,880,539
2024-05-31	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.9K sh	—	—	17,901
2023-06-01	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+4,216 sh	—	—	1,874,572
2023-06-01	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.6K sh	—	—	12,649
2023-01-03	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+165 sh	—	—	2,434
2023-01-03	REGNREGENERON PHARMACEUTICALS, INC.A Award	Director	AAward	+165 sh	—	—	2,434
2023-01-03	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+1,929 sh	—	—	1,929
2023-01-03	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+1,929 sh	—	—	1,929
2022-11-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−20K sh	$30.48	−$610K	1,870,356
2022-11-02	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−11.3K sh	$30.33	−$341K	1,890,356
2022-11-01	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−8,748 sh	$30.20	−$264K	1,901,608
2022-10-03	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,612 sh	$413.33	+$1.49M	5,881
2022-10-03	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−3,612 sh	$718.00	−$2.59M	2,269
2022-10-03	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,612 sh	—	—	0
2022-09-30	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,428 sh	$413.33	+$1.42M	5,697
2022-09-30	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−3,428 sh	$698.00	−$2.39M	2,269
2022-09-30	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,428 sh	—	—	3,612
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,798 sh	$413.33	+$1.57M	6,067
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−16 sh	$686.89	−$11K	6,051
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−321 sh	$687.90	−$221K	5,730
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−637 sh	$688.71	−$439K	5,093
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−1,009 sh	$689.56	−$696K	4,084
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−692 sh	$690.65	−$478K	3,392
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−554 sh	$691.59	−$383K	2,838
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−85 sh	$696.13	−$59.2K	2,753
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−160 sh	$697.29	−$112K	2,593
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−208 sh	$698.44	−$145K	2,385
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−80 sh	$699.82	−$56K	2,305
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−16 sh	$702.36	−$11.2K	2,289
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−20 sh	$704.83	−$14.1K	2,269
2022-09-29	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,798 sh	—	—	7,040
2022-09-28	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−15.6K sh	$30.74	−$479K	1,914,779
2022-09-28	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−4,423 sh	$31.08	−$137K	1,910,356
2022-08-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−19.9K sh	$31.61	−$629K	1,930,456
2022-08-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−100 sh	$32.43	−$3,243	1,930,356
2022-07-25	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−19.8K sh	$35.60	−$705K	1,950,556
2022-07-25	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−200 sh	$36.15	−$7,230	1,950,356
2022-06-24	DNLIDenali Therapeutics Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	$30.53	−$1.22M	1,977,122
2022-06-24	DNLIDenali Therapeutics Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−6,766 sh	$31.08	−$210K	1,970,356
2022-06-23	DNLIDenali Therapeutics Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−13.3K sh	$31.10	−$412K	2,017,106
2022-06-02	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+5,986 sh	—	—	2,030,356
2022-06-02	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+18K sh	—	—	17,959
2022-03-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−8,402 sh	$33.40	−$281K	2,035,968
2022-03-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−11.6K sh	$34.14	−$396K	2,024,370
2022-03-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−8,402 sh	$33.40	−$281K	2,035,968
2022-03-23	DNLIDenali Therapeutics Inc.S Sale	Director	SSale	−11.6K sh	$34.14	−$396K	2,024,370
2022-03-21	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+7,439 sh	$380.95	+$2.83M	9,708
2022-03-21	REGNREGENERON PHARMACEUTICALS, INC.S Sale	Director	SSale	−7,439 sh	$690.00	−$5.13M	2,269

Recent filings

Accepted (ET)
Jun 54
Tessier-Lavigne Marc0001714899-25-000136
SEC(opens sec.gov)
Jun 44
Tessier-Lavigne Marc0001714899-24-000140
SEC(opens sec.gov)
Jun 54
Tessier-Lavigne Marc0001714899-23-000099
SEC(opens sec.gov)
Jan 54
Tessier-Lavigne Marc0001883850-23-000014
SEC(opens sec.gov)
Jan 54
Tessier-Lavigne Marc0001883850-23-000015
SEC(opens sec.gov)
Nov 284
Tessier-Lavigne Marc0001714899-22-000148
SEC(opens sec.gov)
Nov 34
Tessier-Lavigne Marc0001714899-22-000146
SEC(opens sec.gov)
Oct 34
Tessier-Lavigne Marc0001883850-22-000072
SEC(opens sec.gov)

Companies

Address

1 DNA WAY

SO SAN FRANCISCO, CA, 94080